TABLE OF CONTENTS

Acknowledgment to Supplement Reviewers ......................................................... 2638s

Overview
  James L. Mulshine .................................................................................. 2639s

Methods and Strategies in Lung Cancer Control
  Andre Castonguay .................................................................................. 2641s

New Approaches to Treating Early Lung Cancer
  Jack A. Roth ........................................................................................... 2652s

Application of Molecular Genetics to the Early Diagnosis and Screening of Lung Cancer
  Michael J. Birrer and Powel H. Brown .................................................... 2658s

Clinical Significance of ras Oncogene Activation in Human Lung Cancer
  Sjoerd Rodenhuis and Robert J. C. Slebos ............................................. 2665s

Primary Lung Tumors in Mice: An Experimentally Manipulable Model of Human Adenocarcinoma
  Alvin M. Malkinson ................................................................................. 2670s

Induction and Spontaneous Regression of Intense Pulmonary Neuroendocrine Cell Differentiation in a Model of Preneoplastic Lung Injury
  Mary E. Sunday and Christopher G. Willett ........................................... 2677s

Bronchial and Pulmonary Carcinogenesis at Focal Sites in Dogs and Hamsters
  John R. Benfield and William G. Hammond ........................................... 2687s

Lung Cancer Detection and Prevention: Evidence for an Interaction between Smoking and Genetic Predisposition

DNA and Hemoglobin Adducts as Markers of Metabolic Activation of Tobacco-specific Carcinogens
  Peter G. Foiles, Sharon E. Murphy, Lisa A. Peterson, Steven G. Carmella, and Stephen S. Hecht .......................................................... 2698s

Chromosome Abnormalities in Human Non-Small Cell Lung Cancer
  Joseph R. Testa and Jill M. Siegfried ....................................................... 2702s

Determination of Biomarkers for Intermediate End Points in Chemoprevention Trials
  Jin S. Lee, Scott M. Lippman, Waun K. Hong, Jae Y. Ro, Sun Y. Kim, Reuben Lotan, and Walter N. Hittelman ......................................................... 2707s

Considerations in Bringing a Cancer Biomarker to Clinical Application
  Melvyn S. Tockman, Prabodh K. Gupta, Norman J. Pressman, and James L. Mulshine .......................................................... 2711s

New Potential Chemopreventive Agents for Lung Carcinogenesis of Tobacco-specific Nitrosamine
  Fung-Lung Chung, Mark A. Morse, and Karin I. Eklin .............................. 2719s

Nitrosamine-induced Lung Carcinogenesis and Ca^{2+}/Calmodulin Antagonists
  Hildegard M. Schüller ............................................................................. 2723s

Urinary Levels of Bombesin-like Peptides in Asymptomatic Cigarette Smokers: A Potential Risk Marker for Smoking-related Diseases
  Samuel M. Aguayo, Talmadge E. King, Jr., Madeleine A. Kane, Karen M. Sherritt, Wayne Silvers, Louise M. Nett, Thomas L. Petty, and York E. Miller ................................. 2727s

Neuromedin B Is Present in Lung Cancer Cell Lines
  G. Giaccone, J. Battey, A. F. Gazdar, H. Oie, M. Draoui, and T. W. Moody .......................................................... 2732s

Growth of Small Cell Lung Cancer Cells: Stimulation by Multiple Neuropeptides and Inhibition by Broad Spectrum Antagonists in Vitro and in Vivo
  Tariq Sethi, Simon Langdon, John Smyth, and Enrique Rozengurt .......... 2737s

The Correct Dose: Pharmacologically Guided End Point for Anti-Growth Factor Therapy
  James L. Mulshine, Noriyuki Shuke, Farhad Daghighian, Jorge Carrasquillo, Bimal Ghosh, Thomas Walsh, Ingailill Avis, James C. Reynolds, Frank Cuttitta, and Steven M. Larson ........................................ 2743s

2637s
Early Intervention in Cancer Using Monoclonal Antibodies and Other Biological Ligands: Micropharmacology and the “Binding Site Barrier”
John N. Weinstein and William van Os dol ............................................................ 2747s

The Clinical Evaluation of Cancer Chemoprevention Agents: Defining and Contrasting Phase I, II, and III Objectives
Gary E. Goodman .......................................................... 2752s

Chemoprevention Strategies for Lung and Upper Aerodigestive Tract Cancer
Steven E. Benner, Scott M. Lippman, and Waun Ki Hong .................................... 2758s

Preclinical Research in Early Lung Cancer: Breakout Group Report
M. Mabry, T. W. Moody, and S. B. Bay lin .......................................................... 2764s

Diagnostic Research: Breakout Group Report
James L. Mul shine and Melvyn S. Tockman ....................................................... 2766s

Intervention Approaches in Early Lung Cancer and Premalignant Disease: Breakout Group Report
Daniel C. Ihde and Scott Lippman ................................................................. 2767s

List of Participants .......................................................................................... 2769s

Acknowledgment to Supplement Reviewers

Stephen B. Bay lin, Johns Hopkins University, Baltimore, Maryland
Michael Birrer, Biomarkers and Prevention Research Branch, NCI, Rockville, Maryland
Otis Brawley, Division of Cancer Prevention and Control, NCI, Rockville, Maryland
Frank Cuttitta, Biomarkers and Prevention Research Branch, NCI, Rockville, Maryland
David S. Ettinger, Johns Hopkins University School of Medicine, Baltimore, Maryland
Waun K. Hittelman, M. D. Anderson Cancer Center, Houston, Texas
Walter N. Hittelman, M. D. Anderson Cancer Center, Houston, Texas
Bruce E. Johnson, NCI-Navy Medical Oncology Branch, Bethesda, Maryland
John P. Jones, Biomarkers and Prevention Research Branch, NCI, Rockville, Maryland
Ilan Kirsh, NCI-Navy Medical Oncology Branch, Bethesda, Maryland
Barnet S. Kramer, Division of Cancer Prevention and Control, NCI, Bethesda, Maryland
Jin S. Lee, M. D. Anderson Cancer Center, Houston, Texas
Mack Mabry, Johns Hopkins University, Baltimore, Maryland
York E. Miller, University of Colorado, Denver, Colorado
Terry W. Moody, George Washington University, Washington, DC
James L. Mul shine, Biomarkers and Prevention Research Branch, NCI, Rockville, Maryland
Jack A. Roth, M. D. Anderson Cancer Center, Houston, Texas
Hildegard M. Schüller, University of Tennessee, Knoxville, Tennessee
Gail L. Shaw, Biomarkers and Prevention Research Branch, NCI, Rockville, Maryland
Jill M. Siegfried, University of Pittsburgh, Pittsburgh, Pennsylvania
Thomas J. Slaga, University of Texas Systems Cancer Center, Smithville, Texas
Mary E. Sunday, Harvard University, Boston, Massachusetts
Melvyn S. Tockman, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland